Innovation and Global Clinical Trial Participation are the Focus of CenterWatch's Latest Special Report on China's Drug Developmen...( CenterWatch ...),Health

CenterWatch set to release the latest report in its series on emerging markets of clinical research, China: A New Era of Innovation in Drug Development.

Boston, MA (PRWEB) September 29, 2099 -- China's new investments in its domestic pharma industry are beginning to drive growth and reforms that are stimulating a new drug development culture, according to CenterWatch's latest special report, China: A New Era of Innovation in Drug Development.

Scheduled for release in early October, the fifth report in CenterWatch's clinical research series reveals the initial benefits of China's efforts and the various reforms in progress, as well as a look at the further initiatives needed to make the country a major player in the drug development arena.

"CenterWatch has analyzed how China's regulatory reforms can spur innovation in the domestic drug development community, as well as benefit Big Pharma that want to include China in their global drug development programs," says Sara Gambrill, senior editor at CenterWatch and author of the report. In addition, the report discusses Big Pharma's long-range plans to invest in the research and development sector and the talent needed in the area to successfully run trials at a global level.

Other key takeaways include a list of select
'/>"/>